Okada N, Fushimi M, Nagata Y, Fukunaga T, Tsutsumi Y, Nakagawa S, Mayumi T
Faculty and Graduate School of Pharmaceutical Sciences, Osaka University, Suita.
Jpn J Cancer Res. 1996 Sep;87(9):952-7. doi: 10.1111/j.1349-7006.1996.tb02125.x.
In the present work, using a previously reported in vivo quantitative tumor-angiogenesis model, we attempted to ascertain whether this animal model is suitable for practical use in monitoring inhibitors of tumor angiogenesis. Mouse sarcoma-180 cells, human A431 cells or rat C6 cells microencapsulated in agarose beads were implanted s.c. into C57BL/6 mice. The level of blood vessel induction at the agarose pellet site was evaluated using mouse hemoglobin enzyme-linked immunosorbent assay on day 10 after implantation. Hydrocortisone, tetrahydro-S, medroxyprogesterone acetate, pentosan polysulfate and suramin inhibited blood vessel growth in our in vivo tumor-angiogenesis assay system, and heparin enhanced the antiangiogenic effects of hydrocortisone and tetrahydro-S. These results are almost entirely consistent with those observed in common assay systems, and suggest that this method may be useful for the identification and quantitative evaluation of inhibitors of tumor angiogenesis.
在本研究中，我们使用先前报道的体内定量肿瘤血管生成模型，试图确定该动物模型是否适用于实际监测肿瘤血管生成抑制剂。将包封在琼脂糖珠中的小鼠肉瘤-180细胞、人A431细胞或大鼠C6细胞皮下植入C57BL/6小鼠体内。在植入后第10天，使用小鼠血红蛋白酶联免疫吸附测定法评估琼脂糖微球部位的血管诱导水平。在我们的体内肿瘤血管生成测定系统中，氢化可的松、四氢-S、醋酸甲羟孕酮、戊聚糖多硫酸盐和苏拉明抑制血管生长，肝素增强了氢化可的松和四氢-S的抗血管生成作用。这些结果与在常见测定系统中观察到的结果几乎完全一致，表明该方法可能有助于肿瘤血管生成抑制剂的鉴定和定量评估。
